Ahmad El Kouzi | SIU School of Medicine

About me

Ahmad El Kouzi, MD, is an Assistant Professor of Neurology and Movement Disorders at Southern Illinois University School of Medicine. He earned a medical degree from Beirut Arab University in Lebanon and completed a residency in Neurology at Southern Illinois University School of Medicine. He completed fellowship training in Movement Disorders at the University of Florida.

He is the recipient of the prestigious Smallwood Fellowship Award and a Recognition of Excellence Award by the Norman Fixel Institute for Neurological Diseases at the University of Florida. Dr. El Kouzi's special interest is in Deep Brain Stimulation to treat Movement Disorders including Parkinson's Disease, Essential Tremor and Dystonia. He is the first author on multiple peer reviewed journal papers and scientific abstracts related to Parkinson's Disease and Deep Brain Stimulation.

He provides care for patients with movement disorders and other neurological diseases at SIU Medicine in Springfield, Illinois. Dr. El Kouzi currently serves as the Director of the Parkinson's Disease Center at SIU Medicine and is the principal investigator on many clinical trials related to Parkinson's Disease.

Gender

Male

Languages spoken

Arabic,

French

Education & training

Positions

Movement Disorders Specialist

Board Certifications

American Board of Psychiatry and Neurology

Medical School

Beirut Arab University

Residency

Southern Illinois University, Springfield, IL (Neurology)

Fellowship

University of Florida

Download my CV

Awards

Recognition of Excellence Award, University of Florida

Clinical trials

Trial

Neurology

Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Dipraglurant (ADX48621) for the Treatment of Dyskinesia in Patients with Parkinson's Disease Receiving Levodopa-based Therapy With or Without Concomitant Dopaminergic Medications

Active recruiting

The purpose of this study is to evaluate the effectiveness, safety, and tolerability of the investigational drug, dipraglurant (ADX48621), in subjects with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID).

Trial

Neurology

AbbVie: A prospective observational study to evaluate the clinical outcomes and burden of disease of PD patients with motor fluctuations not adequately controlled by current PD medications.

Active not recruiting

PROSPECT: This is an observational study and is designed to describe the clinical outcomes and the burden of disease in PD patients with motor fluctuations not adequately controlled by current PD medications.

Trial

Neurology

Roche: A Phase IIB, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early Parkinson's disease

Active recruiting

PADOVA: The purpose of this study is to find out what effects, good and/or bad, prasinezumab versus placebo has on Parkinson’s disease in people who are taking standard medication to manage the disease symptoms.